| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Rutaevin targets the nitric oxide (NO) production pathway in activated macrophages. It inhibits NO production in LPS-induced RAW264.7 macrophages. This inhibition is likely mediated through the suppression of inducible nitric oxide synthase (iNOS) expression or activity, although the exact mechanism has not been fully elucidated. The compound's anti-inflammatory activity makes it a potential candidate for further study in inflammatory diseases.
|
|---|---|
| ln Vitro |
In vitro, rutaevin shows inhibitory activity on nitric oxide (NO) production in lipopolysaccharide-activated RAW264.7 macrophages. It inhibits NO production, suggesting anti-inflammatory potential. The compound's ability to inhibit NO production has been demonstrated in cell-based assays. Rutaevin is a limonoid tetranortriterpenoid with a unique 5β-H configuration, which is opposite to that of most other Rutaceae limonoids.
|
| ln Vivo |
In vivo, rutaevin's anti-inflammatory effects have not been extensively characterized. As an inhibitor of NO production in macrophages, the compound may have potential in treating inflammatory diseases. However, specific in vivo efficacy data in animal models are not extensively detailed in the available literature. Further studies would be required to evaluate its therapeutic potential.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for rutaevin are not typical because the compound inhibits NO production rather than binding to a specific enzyme or receptor. However, its effect on iNOS expression or activity can be assessed using enzyme activity assays with purified iNOS. The compound's ability to inhibit NO production can also be measured using the Griess assay in cell-free systems.
|
| Cell Assay |
In vitro cellular assays for rutaevin are performed using RAW264.7 macrophages. Cells are treated with varying concentrations of rutaevin and stimulated with LPS. Nitric oxide production is measured using the Griess assay. Cell viability is evaluated using MTT assays to ensure that the observed inhibition of NO production is not due to cytotoxicity. iNOS expression is assessed by Western blotting or quantitative PCR.
|
| Animal Protocol |
In vivo animal experiments for rutaevin have not been extensively documented in the available literature. However, to evaluate its anti-inflammatory effects, animal models of inflammation such as carrageenan-induced paw edema or LPS-induced endotoxemia could be used. Detailed protocols are not available in the published literature.
|
| ADME/Pharmacokinetics |
Rutaevin has a molecular weight of 486.51 g/mol and a molecular formula of C26H30O9. It is a limonoid tetranortriterpenoid isolated from Euodia rutaecarpa and various Rutaceae species. The compound should be stored at 4°C, protected from light. Detailed pharmacokinetic parameters such as half-life, Cmax, and bioavailability have not been extensively reported.
|
| Toxicity/Toxicokinetics |
The toxicological profile of rutaevin has not been extensively characterized. As a natural product, rutaevin is generally considered to have a favorable safety profile at therapeutic concentrations. No significant toxicity has been reported in the available literature. However, comprehensive toxicology studies would be necessary to fully assess its safety for clinical development.
|
| References | |
| Additional Infomation |
Rutaevin is a steroidal lactone. It has been reported in Microcystis sijinensis, Fagaroprosis angola, and other organisms with relevant data.
Rutaevin is a limonoid tetranortriterpenoid with anti-inflammatory activity. It is also known as 吴茱萸苦素. Rutaevin shows inhibitory activity on nitric oxide (NO) production in lipopolysaccharide-activated RAW264.7 macrophages. It is isolated from Euodia rutaecarpa and various Rutaceae species. Rutaevin is a research compound with potential applications in inflammatory diseases. |
| Molecular Formula |
C26H30O9
|
|---|---|
| Molecular Weight |
486.511
|
| Exact Mass |
486.189
|
| CAS # |
33237-37-5
|
| PubChem CID |
441805
|
| Appearance |
White to off-white solid powder
|
| Density |
1.44g/cm3
|
| Boiling Point |
714.9ºC at 760 mmHg
|
| Flash Point |
386.2ºC
|
| Index of Refraction |
1.617
|
| LogP |
2.108
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
35
|
| Complexity |
1040
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C[C@@]12CC[C@H]3[C@]([C@@]14[C@H](O4)C(=O)O[C@H]2C5=COC=C5)([C@H](C(=O)[C@@H]6[C@@]37COC(=O)C[C@@H]7OC6(C)C)O)C
|
| InChi Key |
YZMKFMIZNSOPSN-XGTMLCIVSA-N
|
| InChi Code |
InChI=1S/C26H30O9/c1-22(2)17-16(28)18(29)24(4)13(25(17)11-32-15(27)9-14(25)34-22)5-7-23(3)19(12-6-8-31-10-12)33-21(30)20-26(23,24)35-20/h6,8,10,13-14,17-20,29H,5,7,9,11H2,1-4H3/t13-,14-,17-,18-,19-,20+,23-,24-,25-,26+/m0/s1
|
| Chemical Name |
(1R,2R,7S,10R,12R,13S,14R,16S,19S,20S)-19-(furan-3-yl)-12-hydroxy-9,9,13,20-tetramethyl-4,8,15,18-tetraoxahexacyclo[11.9.0.02,7.02,10.014,16.014,20]docosane-5,11,17-trione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0555 mL | 10.2773 mL | 20.5546 mL | |
| 5 mM | 0.4111 mL | 2.0555 mL | 4.1109 mL | |
| 10 mM | 0.2055 mL | 1.0277 mL | 2.0555 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
